Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : neog - Neogen's E.Coli Test adopted by Japan -- Ignore unavailable to you. Want to Upgrade?

To: Mickey Szilagyi who wrote (249)	11/22/1998 4:38:00 PM
From: Kramer	Read Replies (1) \| Respond to of 441

From neog's recent 10Q it looks like they have already closed the deal on the bot tox vaccine. Most of the purchase price was for inventory, so it looks as though neog did get a very good deal... Neog is now the only producer and source for the botulism vaccine! The Brewer challenge sounds like so much noise to me. From the start of the discussions of privatizing the lab there have been challenges, just like with the Liquor Control Commission. But in both cases the Engler administration won out. The 10Q says: NOTE C - ACQUISITIONS In August 1998, the Company purchased certain inventory and technology from BioPort Corporation of Lansing, Michigan. The purchase price consisted of a single cash payment of $600,000. The Company allocated $400,000 of the purchase price to finished goods and bulk toxoid inventories of Type B equine botulism vaccine ("Bot Tox - B"). The remainder of the purchase price was allocated to other assets and consisted primarily of Types A, B, and C botulism seed cultures, manufacturing protocols, quality control procedures and USDA license to manufacture Bot Tox - B. The increase in other non-current assets at August 31, 1998 compared to May 31, 1998 was due to the acquisition of certain assets of BioPort Corporation.